Eisai Co., Ltd.

4523

JP3160400002

Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (87.7%): prescribed drugs, health products, etc.; - other (12.3%): food additives, chemical products, etc. Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).

Employees

11,067

Sector

Pharmaceuticals

Calendar

2024-09-26 - Détachement de for dividende intermédiaire

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5,627.00JPY

Average target price

7,552.94JPY

Spread / Average Target

+34.23%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-09-19 am EDT			5-day change	1st Jan Change
5,756.00 ^JPY	+2.29%		-1.93%	-18.38%

Sep. 14	Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)	CI
Sep. 04	Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024	CI

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)	Sep. 14	CI
Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024	Sep. 04	CI
Eisai Acquires 9 Billion Yen Worth of Shares in August	Sep. 03	MT
Eisai and Biogen's Alzheimer's Drug Leqembi Receives MHRA Approval in Great Britain	Aug. 22	MT
BioArctic AB Partner Eisai Announces Leqembi Authorized for Early Alzheimer's Disease in Great Britain	Aug. 22	CI
UK patients unlikely to get access to Eisai-Biogen's Alzheimer's drug	Aug. 22	RE
SEED Therapeutics Inc. Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications	Aug. 06	CI
Seed Therapeutics, Inc. announced that it expects to receive funding from Eisai Co., Ltd.	Aug. 05	CI
Eisai Attributable Profit Plunges 48% in Fiscal Q1	Aug. 04	MT
Global markets live: Wells Fargo, Nintendo, Apple, Amazon, Alphabet...	Aug. 02
Eisai Co., Ltd., Q1 2025 Earnings Call, Aug 02, 2024	Aug. 02
Biogen lifts 2024 profit forecast on hopes of new product launches	Aug. 01	RE
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest	Jul. 30	RE
Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference	Jul. 30	CI
Global markets live: Apple, 3M Company, Boeing, Honeywell...	Jul. 29
Japan's Nikkei rebounds in broad-based buying after Wall Street comeback	Jul. 29	RE
Japan's Nikkei rebounds in broad-based buying after Wall Street comeback	Jul. 28	RE
CHMP Rejects Marketing Approval for Eisai's Alzheimer's Drug	Jul. 28	MT
Eisai Shares Slump After Alzheimer's Drug Fails to Get Europe Approval	Jul. 28	DJ
Shares of Japan's Eisai tumble after EU rejects Alzheimer's drug	Jul. 28	RE
Lecanemab Fails to Get EU Marketing Approval; Eisai to Seek Reexamination	Jul. 26	DJ
Eisai Co., Ltd. and Biogen Inc. Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union	Jul. 26	CI
Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union	Jul. 26	CI
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug	Jul. 26	RE
Jefferies Cuts Eisai's Estimates on Low Margins for Leqembi Drug	Jul. 23	MT

Eisai Co., Ltd.

Equities